share_log

TG Therapeutics (NASDAQ:TGTX) Shareholders Have Earned a 36% CAGR Over the Last Five Years

TG Therapeutics (NASDAQ:TGTX) Shareholders Have Earned a 36% CAGR Over the Last Five Years

tg therapeutics(納斯達克:TGTX)股東在過去五年中實現了36%的年複合增長率
Simply Wall St ·  09/30 20:57

Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are hard to find, but they can generate massive returns over long periods. Don't believe it? Then look at the TG Therapeutics, Inc. (NASDAQ:TGTX) share price. It's 357% higher than it was five years ago. And this is just one example of the epic gains achieved by some long term investors. Also pleasing for shareholders was the 30% gain in the last three months.

持有長期投資可能會改變生活,當您購買並持有真正優秀的企業時。儘管最好的公司很難找到,但它們可以在長時間內產生巨大回報。不相信?那就看看TG Therapeutics,Inc.(納斯達克股票代碼:TGTX)的股價吧。比五年前高出357%。這只是一些長期投資者取得的史詩般收益的一個例子。對股東來說,過去三個月的30%增長也令人滿意。

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

那麼,讓我們調查一下並查看公司的長期表現是否符合基本業務的進展。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本傑明·格雷厄姆的話來說:「短期市場是一臺投票機,但長期市場是一臺稱重機」。檢查市場情緒如何隨時間推移變化的一種方式是查看公司股價和每股收益(EPS)之間的相互作用。

During the last half decade, TG Therapeutics became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.

在過去的半個十年裏,TG Therapeutics變得盈利。有時,盈利的開始是一個重要的轉折點,可以預示着即將到來的快速盈利增長,從而證明股價將大幅上漲。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。

big
NasdaqCM:TGTX Earnings Per Share Growth September 30th 2024
納斯達克CM:TGTX每股收益增長曆史數據2024年9月30日

It is of course excellent to see how TG Therapeutics has grown profits over the years, but the future is more important for shareholders. This free interactive report on TG Therapeutics' balance sheet strength is a great place to start, if you want to investigate the stock further.

看到tg therapeutics多年來盈利增長當然是令人滿意的,但對股東來說更重要的是未來。如果您想進一步調查這支股票,就可以從這份關於tg therapeutics資產負債表實力的免費互動報告開始。

A Different Perspective

不同的觀點

It's nice to see that TG Therapeutics shareholders have received a total shareholder return of 192% over the last year. That's better than the annualised return of 36% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. If you would like to research TG Therapeutics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

很高興看到tg therapeutics股東在過去一年中獲得了總股東回報率高達192%。這比過去五年中36%的年化回報率更好,表明該公司近來表現更好。鑑於股價勢頭仍然強勁,值得更仔細地觀察這支股票,以免錯失機會。如果您希望更詳細地研究tg therapeutics,您可能會想看看內部人員是否一直在買入或賣出該公司的股份。

Of course TG Therapeutics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,tg therapeutics可能不是最佳的買入股票。因此,您可能希望查看這些免費的成長股集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論